In younger patients (<60 years) with newly diagnosed FLT3-mutated AML, the FLT3 inhibitor midostaurin is commonly added to the standard 7 + 3 induction therapy, as this regimen was approved based on the positive results of the RATIFY trial [66], but older patients were excluded from the study. Here, FLT3 is linked to acute myeloid leukemia.